| Code | CSB-RA006045MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Namilumab, targeting CSF2 (colony-stimulating factor 2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). CSF2 is a hematopoietic growth factor that regulates the proliferation, differentiation, and activation of granulocytes and macrophages. It plays a critical role in immune responses and inflammatory processes, with dysregulated CSF2 signaling implicated in various autoimmune and inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, and acute respiratory distress syndrome. Elevated CSF2 levels have also been associated with certain malignancies and contribute to tumor microenvironment modulation.
Namilumab is a human IgG1 monoclonal antibody that neutralizes GM-CSF activity and has been investigated in clinical trials for rheumatoid arthritis and other inflammatory disorders. This biosimilar antibody provides researchers with a valuable tool for investigating CSF2-mediated pathways, studying inflammatory mechanisms, evaluating potential therapeutic interventions, and exploring the role of GM-CSF in disease pathogenesis. It serves as an essential reagent for immunology and inflammation research applications.
There are currently no reviews for this product.